Toward the simplification of antithrombotic treatment of venous thromboembolism

Annals of Internal Medicine

Volumn 140, Issue 11, 2004, Pages 925-926

  Prandoni, Paolo ^a,b  

^a UNIVERSITY OF PADOVA   (Italy)

^b UNIVERSITY HOSPITAL OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBOCYTIC AGENT; ENOXAPARIN; FONDAPARINUX; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; WARFARIN;

ANTICOAGULATION; DEEP VEIN THROMBOSIS; DRUG HALF LIFE; HUMAN; LUNG EMBOLISM; PRIORITY JOURNAL; REVIEW; VENOUS THROMBOEMBOLISM;

EID: 2542495006     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-140-11-200406010-00015     Document Type: Review

References (12)

1. Gould MK, Dembitzer AD, Doyle RL, Hastie TJ, Garber AM. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized, controlled trials. Ann Intern Med. 1999;130:800-9. [PMID: 10366369]
2. Koopman MM, Prandoni P, Piovella F, Ockelford PA, Brandjes DP, van der Meer J, et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group. N Engl J Med. 1996;334:682-7. [PMID: 8594426]
3. Levine M, Gent M, Hirsh J, Leclerc J, Anderson D, Weitz J, et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med. 1996;334:677-81. [PMID: 8594425]
4. Haverkamp D, Hutten BA, Büller HR, Gallus AS, Lensing AW, Prins MH. The use of specific antidotes as a response to bleeding complications during anticoagulant therapy for venous thromboembolism. J Thromb Haemost. 2003;1:69-73. [PMID: 12871541]
5. Turpie AG, Bauer KA, Eriksson BI, Lassen MR. Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. Arch Intern Med. 2002;162:1833-40. [PMID: 12196081]
6. Büller HR, Davidson BL, Decousus H, Gallus A, Gent M, Piovella F, et al. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis. A randomized trial. Ann Intern Med. 2004;140:867-73.
7. Büller HR, Davidson BL, Decousus H, Gallus A, Gent M, Piovella F, et al. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med. 2003;349:1695-702. [PMID: 14585937]
8. Büller HR. Factor Xa is a superior target to factor IIa for antithrombotic therapies. Semin Thromb Hemost. 2003;29 Suppl 1:37. [PMID: 14730477]
9. Brandjes DP, Heijboer H, Büller HR, de Rijk M, Jagt H, ten Cate JW. Acenocoumarol and heparin compared with acenocoumarol alone in the initial treatment of proximal-vein thrombosis. N Engl J Med. 1992;327:1485-9. [PMID: 1406880]
10. Prandoni P, Lensing AW, Büller HR, Carta M, Cogo A, Vigo M, et al. Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis. Lancet. 1992;339:441-5. [PMID: 1346817]
11. Eriksson H, Wåhlander K, Gustafsson D, Welin LT, Frison L, Schulman S, et al. A randomized, controlled, dose-guiding study of the oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis: THRIVE I. J Thromb Haemost. 2003;1:41-7. [PMID: 12871538]
12. A novel long-acting synthetic factor Xa inhibitor (SanOrg34006) to replace warfarin for secondary prevention in deep vein thrombosis. A Phase II evaluation. J Thromb Haemost. 2004;2:47-53. [PMID: 14717965]